Cord Blood Registry® (CBR®) announces that the company’s abstract submission titled Prevalence of Diseases and Conditions Amenable to Stem Cell Transplant or Infusion Among Families Storing Newborn Stem Cells at a Large Private Cord Blood Bank has been accepted for poster presentation at the combined annual meetings of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT), being held February 26 – March 2 in Grapevine, Texas.
The poster, which presents key findings from a recent survey of families with at least one child who has newborn stem cells stored with CBR, is scheduled for presentation during the pediatric disorders session on Wednesday, February 26. Of the families completing the questionnaire, 1.87% reported an immediate family history of at least one transplant indication and 17.04% reported at least one regenerative indication. The research results provide evidence that among families who store newborn stem cells in private cord blood banks, conditions for which stem cell transplant or infusion may be indicated or under investigation are relatively prevalent, especially for regenerative indications.
CIBMTR is a voluntary research organization of basic and clinical scientists collaborating to provide a unique resource of data and statistical expertise to the scientific community for addressing important issues in hematopoietic cell transplantation.
ASBMT is an international professional membership association of more than 2,000 physicians, investigators and other healthcare professionals promoting blood and marrow transplantation and cellular therapy research, education, scholarly publication and clinical standards.
Press releases created by third-parties do not necessarily represent the thoughts and/or opinions of the ASBMT or the CIBMTR.
About Cord Blood Registry
Cord Blood Registry® (CBR®) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to establish FDA-regulated clinical trials, requiring CBR processed cord blood, for conditions that have no cure today. For more information, visit cordblood.com
Manager, Public Relations & Corporate Communications
(650) 635-1420 | EXT. 255
SOURCE Cord Blood Registry